Pfizer – Global Leader in Innovative Biopharmaceuticals
Pfizer
Pfizer Inc. is an American pharmaceutical company founded in New York in 1849 by cousins Charles Pfizer and Charles Erhart, immigrants from Germany. It is headquartered in New York City — since 2023 in The Spiral building at Hudson Yards. Its shares are listed on the New York Stock Exchange.
Pfizer develops and makes medicines for oncology, immunology, cardiology, endocrinology and neurology, as well as vaccines, including the COVID-19 vaccine Comirnaty developed with Germany's BioNTech. In 2020 it combined its off-patent division Upjohn with Mylan to form Viatris, and in December 2023 it acquired the biotech company Seagen for 43 billion dollars, expanding its oncology portfolio.
Pfizer's cancer medicines include Ibrance (palbociclib), approved by the FDA in February 2015 as the first CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer; in several Latin American countries and in Turkey it is sold as Reampla. Xalkori (crizotinib) is an ALK inhibitor approved in 2011 for ALK-positive non-small cell lung cancer. Zirabev is a biosimilar of bevacizumab (the original is Roche's Avastin), approved in the EU and the US in 2019.
Unifarm carries Pfizer's oncology medicines Ibrance 125 and Reampla 125 (palbociclib), Xalkori (crizotinib) and Zirabev 400 (bevacizumab).